Results for this period
Interim period (second quarter)1 January 2026–30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company recorded business revenue of ¥36.700 million from research support payments and other income under a joint drug discovery research agreement, while incurring business expenses of ¥283.087 million, including ¥132.404 million in research and development expenses. In addition, an extraordinary loss was incurred due to a ¥141.677 million impairment loss on building附属設備 and tools, furniture and fixtures.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥36 million (YoY -15.5%) |
| Operating profit | ¥-246 million |
| Ordinary income | ¥-243 million |
| Profit attributable to owners of the parent | ¥-386 million |
| Net income per share | (¥59.60) |
| Equity ratio | End of the current fiscal period 92 / End of previous period 94.6 |
| Total assets | ¥1,519 million |
| Net assets | ¥1,397 million |
| Cash flows from operating activities | ¥-282,144 thousand |
| Cash flows from investing activities | ¥387,236 thousand |
| Cash flows from financing activities | ¥0 thousand |
| Cash and cash equivalents at end of period | ¥430,305 thousand |
| Full-year earnings forecast | Net Sales ¥113 million (YoY +24.2%) / Operating profit ¥-569 million / Ordinary income ¥-564 million / Net income ¥-567 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥2,190 thousand |
| Impairment loss | ¥141,677 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥141,677 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts; individual investors |
| Issued Shares at Period-End | 6,487,114 shares |
| Treasury Shares at Period-End | — shares |
| Factors Behind Changes in Business Performance | The company recorded business revenue of ¥36.700 million from research support payments and other income under a joint drug discovery research agreement, while incurring business expenses of ¥283.087 million, including ¥132.404 million in research and development expenses. In addition, an extraordinary loss was incurred due to a ¥141.677 million impairment loss on building附属設備 and tools, furniture and fixtures. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company recorded business revenue of ¥36.700 million from research support payments and other income under a joint drug discovery research agreement, while incurring business expenses of ¥283.087 million, including ¥132.404 million in research and development expenses. In addition, an extraordinary loss of ¥141.677 million was incurred as a result of impairment charges on building附属設備 and tools, furniture and fixtures placed into use during the fiscal year.